Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xeris Pharmaceuticals Inc

4.95
-0.0600-1.20%
Post-market: 4.960.0100+0.20%19:58 EDT
Volume:3.01M
Turnover:14.74M
Market Cap:792.77M
PE:-16.45
High:5.02
Open:4.94
Low:4.70
Close:5.01
Loading ...

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
27 Feb

Press Release: Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025

Dow Jones
·
27 Feb

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
26 Feb

Xeris Biopharma CEO Ken Johnson to retire, Anh Nguyen to succeed

TIPRANKS
·
24 Feb

Xeris Appoints Anh Nguyen, Md, MBA as Chief Medical Officer

THOMSON REUTERS
·
24 Feb

Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

Business Wire
·
24 Feb

Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 50% stake, while 45% is held by institutions

Simply Wall St.
·
19 Feb

Prem Watsa's Strategic Moves: CVS Health Corp Takes Center Stage with 7.82% Portfolio Share

GuruFocus.com
·
14 Feb

Xeris to Participate in Upcoming Investor Conferences

Business Wire
·
05 Feb

the American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

THOMSON REUTERS
·
21 Jan

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Quanterix (QTRX) and Walgreens Boots Alliance (WBA)

TIPRANKS
·
15 Jan

Xeris Biopharma Lifts 2024 Revenue Guidance

MT Newswires Live
·
10 Jan

BRIEF-Xeris Expects To Exceed Full-Year 2024 Financial Guidance

Reuters
·
10 Jan

Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M

TIPRANKS
·
10 Jan

Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter

Benzinga
·
10 Jan

Xeris Biopharma Holdings Inc FY2024 REV View $199.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
10 Jan

Xeris Biopharma Holdings Inc: Full-Year 2024 Total Revenue Projected to Be $203 Mln

THOMSON REUTERS
·
10 Jan

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

THOMSON REUTERS
·
10 Jan

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Business Wire
·
10 Jan

BRIEF-Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
07 Jan